M. Vovk

Eleven years of experience with AIDS-related lymphomas at the Institute of Oncology Ljubljana

T. Mesti, T. Šetina, M. Vovk, 2012, Medical Oncology.

Involved-field radiotherapy for advanced Hodgkin's lymphoma.

J. Raemaekers, A. Hagenbeek, J. Baars, 2003, The New England journal of medicine.

Coexistent hairy cell leukaemia and hepatosplenic t-cell lymphoma: a case report

M. Vovk, V. Kloboves-Prevodnik, G. Gasljevic, 2014, Diagnostic Pathology.

Testing of mechanisms of action of rituximab and clinical results in high-risk patients with aggressive CD20+ lymphoma

S. Novaković, T. Šetina, M. Vovk, 2007 .

A single-center study of treatment outcomes and survival in patients with primary gastric lymphomas between 1990 and 2003

T. Južnič Šetina, B. Jezeršek Novaković, M. Vovk, 2006, Annals of Hematology.

Rituximab affects the prognosis of patients with nonHodgkin' s lymphomas

S. Borstnar, M. Vovk, B. Novakovič, 2004 .

Reactivation of hepatitis B but not hepatitis C in patients with malignant lymphoma and immunosuppressive therapy. A prospective study in 305 patients.

M. Vovk, S. Markovič, G. Drozina, 1999, Hepato-gastroenterology.

Patients with stage III/IV Hodgkin's disease in partial remission after MOPP/ABV chemotherapy have excellent prognosis after additional involved-field radiotherapy: interim results from the ongoing EORTC-LCG and GPMC phase III trial. The EORTC Lymphoma Cooperative Group and Groupe Pierre-et-Marie-Cu

J. Raemaekers, A. Hagenbeek, E. Noordijk, 1997, Annals of oncology : official journal of the European Society for Medical Oncology.

Combined-modality therapy for clinical stage I or II Hodgkin's lymphoma: long-term results of the European Organisation for Research and Treatment of Cancer H7 randomized controlled trials.

J. Raemaekers, A. Hagenbeek, E. Noordijk, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.